Skip to content
Screener

MoonLake Immunotherapeutics MLTX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$1.69M+107%
Alumis Inc. logo
Alumis Inc.ALMS
$15.95M+12.1%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$915K-39.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.1M-10.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$7.71M-33.0%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.47B-56.5%
Enterprise value$1.28B-59.6%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
Line itemMarch 31, 2026December 31, 2025
Weighted average remaining lease term28 months22 months
Weighted average discount rate6.4%4.6%

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's operating lease ROU assets?
MoonLake Immunotherapeutics (MLTX) reported operating lease ROU assets of 6.4% in Q1 2026.
How has MoonLake Immunotherapeutics's operating lease ROU assets changed year-over-year?
MoonLake Immunotherapeutics's operating lease ROU assets increased by 36.2% year-over-year, from 4.7% to 6.4%.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about MoonLake Immunotherapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude